---
title: "002773.SZ (002773.SZ) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/002773.SZ/news.md"
symbol: "002773.SZ"
name: "002773.SZ"
parent: "https://longbridge.com/en/quote/002773.SZ.md"
datetime: "2026-05-21T07:13:13.920Z"
locales:
  - [en](https://longbridge.com/en/quote/002773.SZ/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/002773.SZ/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/002773.SZ/news.md)
---

# 002773.SZ (002773.SZ) — Related News

### [KHPG: "KH812 Intravitreal Injection" drug clinical trial approved](https://longbridge.com/en/news/286896581.md)
*2026-05-19T10:41:03.000Z*
> KHPG's wholly-owned subsidiary Chengdu KHPG Biotechnology Co., Ltd. recently received the "Drug Clinical Trial Approval 

### [The A-share landscape of 34 biopharmaceutical companies: Under the iceberg, who is swimming naked, and who has armor?](https://longbridge.com/en/news/284989987.md)
*2026-05-03T09:28:23.000Z*
> In 2025, the 34 listed companies in the A-share biopharmaceutical industry submitted their performance reports, showing 

### [KHPG released its first-quarter performance, with a net profit attributable to the parent company of 307 million yuan, a year-on-year decrease of 23.13%](https://longbridge.com/en/news/283688699.md)
*2026-04-22T14:53:04.000Z*
> KHPG released its Q1 2026 performance, with operating revenue of 1.046 billion yuan, a year-on-year decrease of 12.70%; 

### [Healthcare Industry Daily (04.19): Frontline Dynamics in Pharmaceuticals](https://longbridge.com/en/news/283262830.md)
*2026-04-19T19:11:18.000Z*
> KHPG's subsidiary KHN921 injection has received FDA clinical trial approval for the indication of hypertrophic cardiomyo

### [KHPG's subsidiary KHN921 injection has received approval from the U.S. FDA to conduct clinical trials](https://longbridge.com/en/news/283250018.md)
*2026-04-19T10:24:03.000Z*
> KHPG's subsidiary Chengdu Hongji Biotechnology Co., Ltd. recently received approval from the U.S. FDA to conduct clinica